Search

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Boehringer Shows Support for Children with Skin Conditions

This year, Boehringer Ingelheim joined campers at Camp Discovery in Millville, PA to demonstrate its support for those facing chronic skin conditions.

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Full data announced in DINAMO trial in young people with T2D

Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Real-world study shows sequencing of Gilotrif

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

From the archives: Maria Plum’s story as a pioneer of her time

Maria Plum was one of the first female lawyers in Germany, and she served as legal counselor for our company starting in the 1930s. Read account of her story written by Katrin Lege, Head of the Boehringer Ingelheim Company Archives, who discovered details

Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines

The findings demonstrate the benefit of clinic-level educational interventions

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

Boehringer Ingelheim Grass Roots Innovation: Supporting life-science innovators

Boehringer Ingelheim Grass Roots Innovation program supports life-science innovators with mentoring, networking and education activities to help them advance their science

Celebrating the power of people and their experiences: Observations for Hispanic/ Latinx Heritage Month

Our Boehringer colleagues share how their experiences with their culture have influenced their approach to life and work.

FDA approves treatment option for T2D in children 10 and older

FDA has approved Jardiance® (empagliflozin) tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. See Safety, PI & Med Guide.

Ensuring Global Access to Corona Care | Boehringer Ingelheim US

BI has signed a communiqué with the Bill & Melinda Gates Foundation and 15 other companies committing to provide access to COVID-19 related services.

Collaboration with Mary Tyler Moore Vision Initiative

Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes

Recognizing Parents Supporting Other Parents

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Recognized as an inclusive workplace for the fifth time

Recognized as an Inclusive Workplace for the Fifth Time

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Prescription Digital Therapeutics a New Frontier in Mental Health Care

Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers